CAPRICOR THERAPEUTICS
Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.
CAPRICOR THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2005-01-01
Address:
Los Angeles, California, United States
Country:
United States
Website Url:
http://www.capricor.com
Total Employee:
11+
Status:
Active
Contact:
(310) 358-3200
Total Funding:
66.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Sitelinks Search Box
Similar Organizations
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Nucleonics
Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Capricor Therapeutics
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Capricor Therapeutics
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Capricor Therapeutics
Cedars Sinai
Cedars Sinai investment in Post-IPO Equity - Capricor Therapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Post-IPO Equity - Capricor Therapeutics
Broadview Ventures
Broadview Ventures investment in Post-IPO Equity - Capricor Therapeutics
Calmedica
Calmedica investment in Post-IPO Equity - Capricor Therapeutics
Beechwood Ventures
Beechwood Ventures investment in Post-IPO Equity - Capricor Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-02 | Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development |
Official Site Inspections
http://www.capricor.com Semrush global rank: 3.6 M Semrush visits lastest month: 3.98 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Capricor Therapeutics"
Capricor Therapeutics - Crunchbase Company Profile
Organization. Capricor Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Capricor Therapeutics is a clinical-stage biotechnology company that focuses …See details»
Capricor Therapeutics to Present Exosome Platform Updates at the ...
May 9, 2024 About Capricor Therapeutics. Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based …See details»
(Nasdaq: CAPR) (@capricortherapeutics) - Instagram
6,194 Followers, 136 Following, 515 Posts - (Nasdaq: CAPR) (@capricortherapeutics) on Instagram: "Capricor is a biotechnology company focused on the development of cell & …See details»
Capricor, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Capricor, Inc. with its drug pipeline, therapeutic area, technology platform, 12 clinical trials, 67 news, and 15 literature, Drug:Deramiocel, Cenderitide. ... The statistics for drugs in …See details»
Capricor Therapeutics, Inc. | LinkedIn
Capricor Therapeutics, Inc. | 9,477 followers on LinkedIn. Capricor (NASDAQ: CAPR) is a biotechnology company developing cell and exosome-based therapeutics for serious …See details»
Capricor Therapeutics - Funding, Financials, Valuation & Investors
Capricor Therapeutics is a biotechnology company focusing on cell and exosome-based therapeutics. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How …See details»
Capricor Therapeutics, Inc. (CAPR)
Nov 12, 2024 Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond. We are patient-focused first, while advancing precision medicine. Learn More …See details»
Capricor Therapeutics Announces Positive Long-Term Data
Oct 11, 2024 Capricor Company Contact: AJ Bergmann, Chief Financial Officer [email protected] 858.727.1755 ...See details»
Capricor Therapeutics to Present Long-Term Data from HOPE-2
Oct 4, 2024 More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as …See details»
Capricor Therapeutics to Present at Upcoming Investor Conferences
Mar 21, 2024 CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation. …See details»
Capricor Therapeutics, Inc. (CAPR) - Yahoo Finance Canada
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne …See details»
The Lancet Publishes Positive Results from Capricor Therapeutics’ …
SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome …See details»
Capricor unlikely impacted by Phan warning letter, says ... - Nasdaq
4 days ago JonesResearch says shares of Capricor Therapeutics (CAPR) saw some volatility over an FDA warning letter issued to an investigator involved in the deramiocel HOPE-3 study, …See details»
Deramiocel's Promise Brightens Capricor's Outlook, With Strings ...
2 days ago Capricor is hoping that Phase 2 data from the HOPE-2 trial, HOPE-2 open-label extension data, and natural history data will be sufficient for approval. If approved, deramiocel …See details»
Table of Contents - capricor.com
Capricor Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 88-0363465 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer …See details»
News Release - NS Pharma
Organization trusted by the community. Please visit our website (https://www.nippon- ... Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing …See details»
CapriCore Management Solutions
Capricore Management Solutions, LLC provides expert HOA and property management services with a focus on integrity, efficiency, and personalized care. Our team handles financials, …See details»
Capricor Therapeutics Reports Third Quarter 2023 Financial Results …
Nov 14, 2023 More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2022, …See details»
Capricorn Organization & Efficiency - InnerSelf.com
By Ted PanDeva Zagar. A practical earth sign, Capricorn (December 22 to January 19) is the month when fanciful dreams become well-plotted schemes. It took Benjamin Franklin (born …See details»